| Similar Articles |
|---|
 |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.   |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Bio-IT World
February 18, 2004 |
Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies |
Nurse Practitioner
November 2010
Dreadin & Mancuso |
Diagnostic breast evaluation: When to refer and what the results really mean Diagnostic breast imaging is an important tool in evaluating abnormal physical examination findings and assessing incomplete screening mammographic results. |
Pharmaceutical Executive
March 1, 2013
Keeling & Paz |
Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics. |
Managed Care
August 2007
Thomas Morrow |
Gene Expression Microarray Improves Prediction of Breast Cancer Outcomes Flash-frozen samples of surgically removed breast cancer tissue are the key to measuring a patient's risk of metastasis. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Pharmaceutical Executive
February 1, 2013
William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
Bio-IT World
April 16, 2004 |
Portraits in Proteomics Advances in identifying protein biomarkers are spurring new hope in cancer diagnostics, expediting detection and easing testing. |
Pharmaceutical Executive
October 1, 2010 |
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
Nurse Practitioner
December 2011
Downs-Holmes & Silverman |
Breast cancer: Overview & updates This overview of breast cancer will discuss pathologic features, local and systemic treatment considerations, endocrine therapy, metastatic treatment regimens, and follow-up for optimal breast health. |
Chemistry World
December 16, 2013
Michael Parkin |
1024 samples analysed on a single chip Researchers in Switzerland have developed a microfluidic platform able to measure four protein biomarkers in over 1000 blood samples on a single microfluidic chip. |
Nurse Practitioner
October 2009
Wallace et al. |
Shedding light on prostate cancer This article will discuss the risk factors, signs and symptoms, diagnosis of prostate cancer, and disease staging and grading, as well as necessary lab and diagnostic tests, treatment options and patient education. |
Pharmaceutical Executive
September 1, 2011
Don Creighton |
Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement. |
Pharmaceutical Executive
November 1, 2013 |
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation. |
HHMI Bulletin
Nov 2010 |
Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers. |
Bio-IT World
June 2006
Kevin Davies |
The Data Deluge: Deal or No Deal? Far from decrying the data glut, researchers should embrace the complexity of genomic and other sources of data, particularly for its predictive properties in the field of personalized medicine. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
Bio-IT World
October 2005
Mark D. Uehling |
HistoRx Automates Pathology The company offers a platform called Aqua, which can perform automated, in situ analysis of protein expression levels on tissue microarrays in less than an hour. The company has promising projects in melanoma and breast cancer. |
Pharmaceutical Executive
August 1, 2012
Debbie Warner |
Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder. |
Pharmaceutical Executive
July 1, 2012
Jill Wechsler |
Who Will Pay for New Drugs? Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. |
Wired
Thomas Goetz |
Why Early Detection Is the Best Way to Beat Cancer By getting regular blood tests, doctors may be able to diagnose cancer early, giving the patient a 90 percent chance of survival. |
The Motley Fool
April 20, 2010
Jim Mueller |
Better, Targeted Drugs, Dead Ahead Personalized medicine is becoming a reality that will help patients, companies, and investors. |
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? |
Bio-IT World
February 11, 2005
Robert M. Frederickson |
Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
Pharmaceutical Executive
January 1, 2009
Amit Agarwal |
Overlooked Opportunities For pharma companies facing a difficult economic climate, pairing diagnostics with therapies offers a powerful incentive: Manufacturers can improve sales by helping physicians find the most appropriate therapeutic option. |
Pharmaceutical Executive
September 1, 2010 |
The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development. |
Scientific American
March 2009
Elaine Schattner |
A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment |
Pharmaceutical Executive
March 1, 2011
Jerry Coamey |
Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution |
Chemistry World
January 21, 2011
Jennifer Newton |
Early lung cancer diagnosis Patients with lung cancer have elevated levels of a specific protein in their blood that could be used as a biomarker for the disease, say scientists from South Korea. |
Nursing
April 2009
Colwell & Gordon |
Helping patients combat colon cancer Colorectal cancer is the third most frequently diagnosed cancer in the United States. In 2008, about 148,810 people received this diagnosis and an estimated 49,960 died of the disease. |
Pharmaceutical Executive
September 1, 2012
Robin Hertz |
The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life. |
Fast Company
David Lumb |
Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period. |
Bio-IT World
March 8, 2005
Patricia Reilly |
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending. |
Wired
July 2006
Kevin Kelleher |
Personalize It While Adidas offers customized shoes for your feet, the pharmaceutical industry is moving toward personalizing drugs based on your genes. |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
Pharmaceutical Executive
June 1, 2006
Nancy Dreyer |
Personalized Medicine Meets the Real World A wave of genomic medicines is coming down the pipeline, and they're going to be expensive. Can companies prove they're worth it? Maybe: but the claims payers seek aren't coming from traditional clinical trials. |
Pharmaceutical Executive
December 1, 2011
Lujing Wang |
The Payoff for Payers Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval. |
Wired
August 2003
Jennifer Kahn |
The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. |
The Motley Fool
May 8, 2009
Brian Orelli |
Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector? |
BusinessWeek
June 6, 2005
Catherine Arnst |
Better Odds Against Breast Cancer New treatments for breast cancer are more effective, and easier to live with |
Bio-IT World
Dec2006 /Jan 2007
Robert M. Frederickson |
Microarrays for Methylation Recent data suggest altered gene methylation patterns contribute to tumor development. Orion Genomics has developed two methods for enzymatic DNA methylation screening. |
American Family Physician
February 15, 2005
Sunga et al. |
Care of Cancer Survivors Cancer survivors are at increased risk for recurrence of their original malignancy. Surveillance following curative cancer treatment generally includes interval history and physical examinations every six months for five years. |
Chemistry World
June 22, 2011
Sarah Houlton |
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe. |
